论文部分内容阅读
目的:探讨氯沙坦联合百令胶囊治疗慢性肾脏病对患者氧化应激、肾功能和微炎症状态的影响。方法:选择浙江省荣军医院2018年9月至2019年9月收治的慢性肾脏病患者94例，按照随机数字表法分为治疗组47例与对照组47例。对照组给予氯沙坦钾片治疗，治疗组在氯沙坦钾片基础上口服百令胶囊治疗。两组疗程均为24周。比较两组治疗前后氧化应激、肾功能和微炎症因子变化，及治疗疗效。结果:治疗组总有效率［91.49%（43/47）］高于对照组［68.09%（32/47）］（χn 2=7.982，n P<0.05）。治疗组治疗后血清超氧化物歧化酶（SOD）［（138.16±5.67）U/L］、谷胱甘肽过氧化物酶（GSH-Px）［（48.20±3.78）U/L］均高于对照组的（119.74±3.64）U/L和（41.36±3.29）U/L，丙二醛（MDA）［（2.78±0.32）mmol/L］低于对照组［（3.21±0.38）mmol/L］，差异均有统计学意义（n t=18.742、9.358、5.934，均n P<0.05）。治疗组治疗后血清尿素氮（BUN）［（4.32±0.45）mmol/L］、肌酐（Cr）［（54.45±8.98）mmol/L］均低于对照组［（6.53±0.62）mmol/L和（78.31±10.16）mmol/L］（n t=19.777、12.063，均n P<0.05）。治疗组治疗后血清肿瘤坏死因子α（TNF-α）［（58.36±6.64）μg/L］、超敏C反应蛋白（hs-CRP）［（3.94±1.25）mg/L］、白细胞介素18（IL-18）［（176.58±17.49）ng/L］均低于对照组［（71.32±6.07）μg/L、（6.87±1.49）mg/L和（229.31±20.09）ng/L］（n t=9.876、10.328、13.572，均n P<0.05）。n 结论:氯沙坦联合百令胶囊可改善慢性肾脏病患者氧化应激、肾功能及微炎症状态，且可获得良好疗效。“,”Objective:To investigate the effects of losartan combined with n Bailing capsule on oxidative stress, renal function and microinflammation in patients with chronic kidney disease.n Methods:Ninety-four patients with chronic kidney disease who received treatment in Rong Jun Hospital from September 2018 to September 2019 were included in this study. They were randomly assigned to receive treatment with either oral losartan (control group, n n = 47) or oral losartan combined with n Bailing capsule (treatment group, n n = 47) for 24 weeks. Preoperative and postoperative oxidative stress, renal function and microinflammatory factor level as well as clinical efficacy were compared between the control and treatment groups.n Results:Total effective rate in the treatment group was significantly higher than that in the control group [91.49% (43/47) n vs. 68.09% (32/47), χn 2 = 7.982, n P < 0.05]. After treatment, superoxide dismutase and glutathione peroxidase levels in the treatment group were significantly higher than those in the control group [superoxide dismutase: (138.16 ± 5.67) U/L n vs. (119.74 ± 3.64) U/L, glutathione peroxidase: (48.20 ± 3.78) U/L n vs. (41.36 ± 3.29) U/L, n t =18.742, 9.358, both n P < 0.05]. After treatment, malondialdehyde level in the observation group was significantly lower than that in the control group [(2.78 ± 0.32) mmol/L n vs. (3.21 ± 0.38) mmol/L, n t = 5.934, n P < 0.05]. After treatment, serum urea nitrogen [(4.32 ± 0.45) mmol/L] and creatinine [(54.45 ± 8.98) mmol/L] in the treatment group were significantly lower than those in the control group [(6.53 ± 0.62) mmol/L and (78.31 ± 10.16) mmol/L, n t = 19.777, 12.063, both n P < 0.05]. After treatment, serum levels of tumor necrosis factor-α [(58.36 ± 6.64) μg/L], hypersensitive C-reactive protein [(3.94 ± 1.25) mg/L] and interleukin-18 [(176.58 ± 17.49) ng/L] in the treatment group were significantly lower than those in the control group [(71.32 ± 6.07) μg/L, (6.87 ± 1.49) mg/L and (229.31 ± 20.09) ng/L, n t = 9.876, 10.328, 13.572, all n P < 0.05].n Conclusion:Losartan combined with n Bailing capsule can improve oxidative stress, renal function and microinflammation in patients with chronic kidney disease and can achieve good clinical efficacy.n